Free Content

PLAIN LANGUAGE SUMMARIES

ASN002 demonstrates efficacy and improves inflammation in AD

Linked article

Article first published online: 01 Oct 2019
DOI: 10.1111/bjd.18398

Comment on this article

Summary

Few medicines are available for the treatment of moderate‐to‐severe atopic eczema. ASN002 is a new oral (taken by mouth) drug being tested that has been shown to reduce the activity of various proteins playing a role in skin inflammation. In the present study, the safety and efficacy of different doses of ASN002, administered once daily for 4 weeks, were evaluated and compared to a placebo in patients with moderate‑to‑severe eczema. The placebo was a tablet made from the same base product used to make ASN002, but that did not contain any active medication. A total of 27 patients received ASN002 and nine patients received the placebo. In general, ASN002 was well tolerated and caused limited side effects, with higher doses of ASN002 not causing more frequent or severe side effects. After four weeks of treatment, patients who received ASN002 had a better improvement in the severity of their eczema compared to patients who received the placebo, and these positive effects were noted as early as two weeks following the start of treatment. Treatment with ASN002 also rapidly improved the degree of itch and was associated with a significant reduction in the level of proteins circulating in the blood that are involved in inflammation. Taken together, the encouraging efficacy and safety profile of ASN002 warrants further investigation of ASN002 in patients with moderate‑to‑severe eczema.

Read moreRead more (PDF)

Share this article

0

Favourite

Comments

If you want to submit a letter for publication rather than comment on an article please submit through Scholar One: https://mc.manuscriptcentral.com/bjd

There are no comments for this article yet.

Recent Tweets

@BrJDermatol

13 Nov 2019

Find out how changing immunosuppressive treatment practices have impacted SCC and BCC cancer risk in organ transplant recipients at https://t.co/wlvY9C1BnB #SCC #BCC #organtransplant #epidemiology https://t.co/tofI5FYhdu

@BrJDermatol

13 Nov 2019

RT The British Association of Dermatologists @HealthySkin4All: We are very excited to be planning the launch of a new open access journal, for which we are now looking for an Editor-in-Chief. Full details and information on how to apply for this role can be found here: https://t.co/42Fego0m99 @BrJDermatol @ced_wiley https://t.co/RAtLL76qpd

@BrJDermatol

13 Nov 2019

RT Dr Katie Farquhar @katiefarquhar: Very interesting article looking at skin cancer trends in transplant recipients from @BrJDermatol https://t.co/ia0PTvQCx9

@BrJDermatol

12 Nov 2019

Why has there been a significant reduction in the incidences of both SCC and BCC in organ transplant recipients over the past two decades? https://t.co/9LZepIh0V0 #SCC #BCC #organtransplant #epidemiology https://t.co/7mFJDPG3ch

@BrJDermatol

12 Nov 2019

RT The British Association of Dermatologists @HealthySkin4All: There is a need for more economic studies which look at the costs and effectiveness of two or more eczema treatments. These types of studies help inform how healthcare resources are used. https://t.co/jXK2mF2WQe @BrJDermatol @Wiley_Health @eczemasociety https://t.co/r90pWBEcRK

@BrJDermatol

11 Nov 2019

Join the discussion regarding the definition and clinical implications of palmoplantar pustulosis at https://t.co/rvMFifNM5l #psoriasis #commentary https://t.co/4BQRcTOq2S

Close